Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Michelle, Melisko"'
Autor:
Jie Jane Chen, MD, Iowis Zhu, PhD, Akshat Patel, MD, Gregor Krings, MD, PhD, Yunn-Yi Chen, MD, PhD, Florence Yuen, NP, Rita A. Mukhtar, MD, Michelle Melisko, MD, Lisa Singer, MD, PhD, Catherine C. Park, MD, Nicolas D. Prionas, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 5, Pp 101448- (2024)
Externí odkaz:
https://doaj.org/article/c42cd15f7fd54c53898ea9502fb0b7fd
Autor:
Helena Record, Elle Clelland, Harriet T. Rothschild, Mandeep Kaur, A. Jo Chien, Michelle Melisko, Hope S. Rugo, Firdows Mujir, Laura Huppert, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer, recent trials showed a benefit of aromatase
Externí odkaz:
https://doaj.org/article/625ef5977e26439abbf8c611535e33d2
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Mary Kathryn Abel, Amy M. Shui, Michelle Melisko, A. Jo Chien, Emi J. Yoshida, Elizabeth M. Lancaster, Laura Van ‘T Veer, Laura J. Esserman, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract When molecular testing classifies breast tumors as low risk but clinical risk is high, the optimal management strategy is unknown. One group of patients who may be more likely to have such discordant risk are those with invasive lobular carc
Externí odkaz:
https://doaj.org/article/b88c275529fe4c4da1b6cfc8c63c7d7e
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Neelima Vidula, Sally Greenberg, Laura Petrillo, Jimmy Hwang, Michelle Melisko, Andrei Goga, Mark Moasser, Mark Magbanua, John W. Park, Hope S. Rugo
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 m
Externí odkaz:
https://doaj.org/article/3a9e793b4485485687e39189dbcf79b3
Autor:
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. Th
Externí odkaz:
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
Autor:
Saumya Umashankar, Matina Elise Mamounas, Madeline Matthys, Edward Kenji Hadeler, Emily Claire Wong, Greg Hicks, Jimmy Hwang, Amy Jo Chien, Hope S Rugo, Deborah Hamolsky, Laura Esserman, Michelle Melisko
Publikováno v:
JMIR Cancer, Vol 8, Iss 1, p e31756 (2022)
BackgroundPatients with breast cancer frequently experience escalation of anxiety after completing curative treatment. ObjectiveThis study evaluated the acceptability and psychological impact of a 1-day workshop to emphasize behavioral strategies in
Externí odkaz:
https://doaj.org/article/4237cee0b1314dd786c38793f0b70b24
Autor:
Amrita Basu, Saumya Umashankar, Kaylee Blevins, Anna Northrop, Anika Christofferson, Ebunoluwa Olunuga, Jaeyoon Cha, Ananya Mittal, Julissa Molina-Vega, Laura Sit, Thelma Brown, Bev Parker, Diane Heditsian, Susie Brain, Carol Simmons, Alessandra Taboada, Tina J. Hieken, Kathryn Ruddy, Carolina Salvador, Candace Mainor, Anosheh Afghahi, Sarah Tevis, Anne Blaes, Irene M. Kang, Jane Perlmutter, Hope Rugo, Sai Kanaparthi, Garry Peterson, Lisa T. Weiss, Adam Asare, Laura J. Esserman, Michelle Melisko, Dawn Hershman
Publikováno v:
Cancer Research. 83:P5-07
Background. Patient-reported outcomes (PROs) are increasingly recognized as a valuable component to understand treatment tolerability and toxicity among patients on clinical trials. We have implemented a system for monitoring patient reported outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83ceaa8ddecc389b4ebe1e9ddb64f749
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-03
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-03